gsk

Jemperli (dostarlimab) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III ...
gsk

GSK provides update on phase I/II therapeutic herpes simplex virus (HSV) vaccine trial

GSK plc (LSE/NYSE: GSK) today announced that it has completed the primary objective data analysis from the phase II part of the TH HSV REC-003 trial. This trial is a combined phase I/II ...
gsk

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or metastatic disease 1 Next-generation design aims to address key efficacy ...
gsk

For media and investors only

ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi B.V. (Shionogi) as shareholders, has announced that the U.S. Food ...
gsk

GSK acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer

Metastatic castration-resistant prostate cancer (mCRPC) remains a significant health burden for men with critical need for novel targeted treatments Agreement adds a new preclinical ADC with potential ...
gsk

European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer

Expanded approval includes MMRp/MSS tumours, which represent approximately 75% of endometrial cancer cases Approval based on RUBY Part 1 trial, which showed a median overall survival (OS) of 44.6 ...
gsk

GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted the company’s regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial ...
gsk

GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation

CureVac will make an upfront settlement of $370 million to GSK GSK will receive a 1% royalty on future Pfizer / BioNTech US sales of influenza, COVID-19 and related combination mRNA vaccine products ...
gsk

Lynn Baxter

Lynn joined the Executive Committee in 2026. As President, Europe, she is responsible for the commercial performance and strategic direction of GSK’s European markets, overseeing a diverse range of ...
gsk

Working with third parties

We work with thousands of third parties across all areas of our business. On this page we detail our third-party policies and practices. Our suppliers and other third parties – including agents, ...
gsk

GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population

ARTEMIS-008, a phase III study conducted for China, met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer First positive phase III overall survival data for a ...
gsk

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK ...